⏳ Fetching live dividend data...
Home › Calculator › GTHX Dividend Calculator 2026
G1 Therapeutics, Inc. · NASDAQ
Price: $7.16 · Annual div: None · Frequency: — · Payout ratio: N/A · Ex-div: —
GTHX is not a dividend-focused stock
GTHX pays a very low or no dividend (Yield: 0.00%). This calculator is designed for income-producing assets. If your goal is passive income and compounding, you might want to look at these popular alternatives:
G1 Therapeutics, Inc. (GTHX) does not currently pay a regular dividend in our data, so its dividend yield is 0%.
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
G1 Therapeutics, Inc. operates as a clinical-stage biopharmaceutical enterprise focused on identifying, advancing, and ultimately commercializing small-molecule therapeutics to address various cancers. Their flagship commercial offering, COSELA, is designed to reduce chemotherapy-induced bone marrow suppression in adult patients with extensive-stage small cell lung cancer, administered prior to specific platinum/etoposide- or topotecan-containing regimens. The company is also actively progressing several investigational compounds. Trilaciclib, a CDK4/6 inhibitor, is currently undergoing extensive clinical evaluation, including Phase III studies for first-line colorectal cancer and first-line triple-negative breast cancer. Additionally, it is in Phase II trials for initial bladder cancer treatment, in combination with an antibody-drug conjugate, and as a neoadjuvant therapy for breast cancer. Their development pipeline further includes lerociclib, an oral CDK4/6 inhibitor intended for multiple oncological applications, and rintodestrant, an orally administered selective estrogen receptor degrader, which is in Phase IIa clinical trials for estrogen receptor-positive, HER2-negative breast cancer. G1 Therapeutics has forged several strategic licensing agreements. They have partnered with EQRx, Inc. and Genor Biopharma Co. Inc. for the oral formulation of lerociclib, encompassing all human indications. A separate collaboration with Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. covers the parenteral development and market introduction of trilaciclib for any human indication. Furthermore, the company works with ARC Therapeutics on a CDK2 inhibitor, designated for both human and veterinary uses. Established in 2008, G1 Therapeutics, Inc. is headquartered in Research Triangle Park, North Carolina.
No. G1 Therapeutics, Inc. (GTHX) has not paid a regular dividend in the last 12 months in our data, so its dividend yield is 0% and it produces no dividend income.
Dividend ETFs such as SCHD, VYM or JEPI pay regular income. Open their DRIP calculators to see what $10,000 would earn per month and how reinvesting grows it.
A DRIP reinvests dividends into new shares. GTHX has no regular dividend in our data, so there is nothing to reinvest.
Forward dividend yield from the latest data · open any DRIP calculator
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open GTHX position with:
Real after-tax yield depends on where you live and how you hold GTHX.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 0.00% | -2.80% | $0 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 0.00% | -2.80% | $0 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 0.00% | -2.80% | $0 / yr |
| 🇬🇧 UK ISA | 0% | 0.00% | -2.80% | $0 / yr |
| 🇬🇧 UK Taxable | 8.75% | 0.00% | -2.80% | $0 / yr |
| 🇨🇦 TFSA | 0% | 0.00% | -2.80% | $0 / yr |
| 🇨🇦 CA Taxable | 25% | 0.00% | -2.80% | $0 / yr |
| 🇦🇺 Super (pension) | 15% | 0.00% | -2.80% | $0 / yr |
| 🇦🇺 AU Taxable | 30% | 0.00% | -2.80% | $0 / yr |
| 🇩🇪 DE Taxable | 26.375% | 0.00% | -2.80% | $0 / yr |
| 🇫🇷 FR Taxable | 30% | 0.00% | -2.80% | $0 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
No dividend data available for this ticker.
Based on current dividend of $0.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
GTHX pays quarterly — 4 times per year. Ex-div: —.
How GTHX compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for GTHX sourced from FMP /financial-growth endpoint — real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| D-Return | 2024-09-18 | 20,000 | $7.15 | $143.0K | ||
| D-Return | 2024-09-18 | 30,000 | $2.99 | $89.7K | ||
| U-Tender | 2024-09-18 | 10,000 | — | — | ||
| D-Return | 2024-09-18 | 30,000 | $2.83 | $84.9K | ||
| D-Return | 2024-09-18 | 30,000 | $5.30 | $159.0K | ||
| D-Return | 2024-09-18 | 138,151 | $7.15 | $987.8K | ||
| U-Tender | 2024-09-18 | 6,674 | — | — | ||
| D-Return | 2024-09-18 | 55,875 | $2.97 | $165.9K | ||
| D-Return | 2024-09-18 | 150,000 | $2.88 | $432.0K | ||
| D-Return | 2024-09-18 | 20,000 | $7.15 | $143.0K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Compare GTHX with peers: GTHX vs CKPT · GTHX vs CLYM · GTHX vs CTEV
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the GTHX dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
G1 Therapeutics, Inc. (GTHX) is currently trading at $7.16, trading near its 52-week high. It does not currently pay a regular dividend.
G1 Therapeutics, Inc. (GTHX) is a healthcare stock trading at $7.16. It does not currently pay a regular dividend in our data, so it produces no dividend income and DRIP reinvestment does not apply. Investors seeking income often look at dividend ETFs such as SCHD, VYM or JEPI instead.
Auto-generated from live market data. For educational purposes only — not financial advice.
If DividendFlow helped you see your future dividend income clearly, other investors deserve the same clarity. Your review takes 30 seconds and makes a real difference.
⏱️ Takes 30 seconds · No signup · Free forever